Abstract: . . .  National Asthma Education and Prevention Program Expert Panel Report Managing Asthma During Pregnancy: Recommendations for Pharmacologic TreatmentUpdate 2004 Evidence Tables U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute i CONTENTS Table . . .
. . .  Comments Purpose/Objective: To report a case of transplacental aminophylline toxicity. Citation 8: Agarwal, Nanavati, Bhagwat, et al. 1998 Case report x Human Age: 26 years Pregnancy trimester: 3rd (40 weeks) Asthma severity: Acute exacerbation unresponsive to salbutamol Arm 1: Aminophylline (250 mg, i.v.) + hydrocortisone with no improvement, then 2 more 250-mg doses of aminophylline 1 1 Length of study: 34 days Length . . .
. . .  and above may g/mL and above may induce toxicity. Page 16 Asthma During Pregnancy Evidence Tables 15 Table 2. Effects of bronchodilatorstheophylline on maternal health and fetal outcomes when used to treat asthma during pregnancy (continued). Study Characteristics Findings Citation/ Study Type Population Arm Number Enrolled Number Evaluable Treatment Duration Outcome 1 Outcome 2 Outcome 3  . . .
. . .  National Asthma Education and Prevention Program Expert Panel Report Managing Asthma During Pregnancy: Recommendations for Pharmacologic TreatmentUpdate 2004 Evidence Tables U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute i CONTENTS Table 1. Effects of bronchodilatorsbeta-agonists . . .
. . .  risk of teratogenic and fetal toxicity is dependent on dosage and that maternal (and fetal) plasma theophylline concentrations of 106 g/mL and above may g/mL and above may induce toxicity. Page 16 Asthma During Pregnancy Evidence Tables 15 Table 2. Effects of bronchodilatorstheophylline on maternal health and fetal outcomes when used to treat asthma during pregnancy (continued). Study Characteristics Findings Citation/ Study Type Population Arm . . .
--3000,5,300,3008,64299